Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid Tumors

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Kadmon Corporation, LLC
ClinicalTrials.gov Identifier:
NCT00086528
First received: July 2, 2004
Last updated: October 17, 2011
Last verified: October 2011

July 2, 2004
October 17, 2011
June 2004
July 2007   (final data collection date for primary outcome measure)
To evaluate the safety and tolerability of XL647 administered orally as a single dose and as repeat doses [ Time Frame: First treatment until 30 days post last treatment ] [ Designated as safety issue: Yes ]
Not Provided
Complete list of historical versions of study NCT00086528 on ClinicalTrials.gov Archive Site
  • To evaluate the plasma pharmacokinetics of XL647 administered orally as a single dose and as repeat dose [ Time Frame: At various time points between pre-treatment and post last treatment ] [ Designated as safety issue: Yes ]
  • To estimate renal elimination of XL647 administered orally as a single dose in subjects with solid tumors [ Time Frame: At various time points between pre-treatment and post last treatment ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
Not Provided
 
Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid Tumors
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid Tumors

The primary objective of this study is as follows:

  • To evaluate the safety and tolerability of XL647 administered orally as a single dose and as repeat doses in subjects with solid tumors.

The secondary objectives of this study are as follows:

  • To evaluate the plasma pharmacokinetics of XL647 administered orally as a single dose and as repeat doses in subjects with solid tumors,
  • To estimate renal elimination of XL647 administered orally as a single dose in subjects with solid tumors.

The exploratory objective of this study is as follows:

  • To assess the pharmacodynamic effects of XL647 administration in plasma and peripheral blood cells.

In addition, subjects may be eligible to enter a Treatment Extension Period. The following information will be obtained from this part of the study:

  • Long-term safety and tolerability of XL647 after repeat administration,
  • Tumor response after repeat administration of XL647.
Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Cancer
Drug: XL647
Administered orally as a solution with mass-based dosing in early cohorts or as 50-mg tablets at a fixed dose at the MTD. A minimum of 3 subjects was planned for each dosing cohort with dose escalation dependent on subject tolerance of the prior dose. During the Treatment Period, subjects in each cohort were administered a single dose of XL647 on Day 1 followed by a 72-hour period of observation. If there were no XL647-related dose limiting toxicities, subjects received 5 daily doses of XL647 on Days 4-8. Twenty-one days after the initial dose, in the absence of unacceptable toxicity or disease progression, subjects could enter a Treatment Extension Period that consisted of repeated 2-week cycles of five oral doses of XL647 followed by a 9-day observation period.
Other Name: KD019
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
41
November 2007
July 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • The subject has a histologically confirmed malignancy that is metastatic or unresectable, and for which standard curative or palliative measures do not exist or are no longer effective,
  • The subject has disease that is assessable by tumor marker, physical, or radiologic means,
  • The subject is ≥18 years old,
  • There have been at least 4 weeks since prior chemotherapy or radiation therapy (6 weeks if the last treatment regimen included BCNU or mitomycin C),
  • The subject has an ECOG performance status ≤2 (Karnofsky >60%),
  • The subject has a life expectancy of ≥3 months,
  • The subject has normal organ and marrow function (hemoglobin >10g/dL, leukocytes >3,000/mL, absolute neutrophil count >1,500/µL, platelets >100,000/µL, total bilirubin within normal institutional limits of normal,AST (SGOT)/ALT(SGPT) <2.5 times the upper limit of normal, and creatinine within normal limits,
  • The subject is capable of understanding and complying with the protocol and has signed the informed consent document,
  • Sexually active subjects (both male and female) must use an accepted method of contraception during the course of the study,
  • Female subjects of childbearing potential (pre-menopausal) must have a negative pregnancy test.

Exclusion Criteria:

  • The subject has had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or has not recovered from AEs due to agents administered more than 4 weeks earlier,
  • The subject has received another investigational agent within 30 days (or 5.5 half-lives) of the first dose of study drug,
  • The subject has known brain metastases,
  • The subject has a corrected QT interval (QTc) of >0.44 seconds,
  • The subject has a history of allergic reactions attributed to aspartame or to any other component in the formulation vehicle,
  • The subject has an uncontrolled intercurrent illness including,but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements,
  • The subject is pregnant or nursing,
  • The subject is known to be positive for the human immunodeficiency virus (HIV).
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00086528
XL647-001
Yes
Kadmon Corporation, LLC
Kadmon Corporation, LLC
Not Provided
Study Director: Harold Keer, M.D., Ph.D. Exelixis, Inc. (Study Sponsor)
Kadmon Corporation, LLC
October 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP